Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2563 - NSCLC Patient Immune Cell Profiling and Response of Tumor­ Antigen­ Specific CD8 T Cells to Checkpoint Receptor Antagonists


11 Sep 2017


Poster display session


Junghee Lee


Annals of Oncology (2017) 28 (suppl_5): v573-v594. 10.1093/annonc/mdx390


J. Lee1, X. Wu2, L. Liu2, M.D. Breyer2, H.K. Kim1, J.H. Cho1, J. Lee3, Y.S. Shin3, J. Kim1, Y. Zhao2

Author affiliations

  • 1 Thoracic And Cardiovascular Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, 06351 - Seoul/KR
  • 2 Biotechnology Discovery Research, Eli Lily and Company, Indianapolis/US
  • 3 Biomedical Science, Samsung Biomedical Research Institute, Samsung Medical Center Sungkyunkwan University School of Medicine, 06351 - Seoul/KR


Abstract 2563


The breakthrough in cancer immunotherapy of targeting PD-1 or PD-L1 and enabling T cells to attack tumor has opened new window for cancer treatment of many tumor types. Many of these immunotherapeutic approaches involve targeting specific immune checkpoints. To better understand the role of checkpoint receptors in cancer immunotherapy and explore new treatments, we analyzed cancer patient PBMCs and dissociated tumor samples from non-small cell lung cancer (NSCLC).


Transcripts of Cancer Testis (CT) antigens (NY-ESO-1, MAGE-A1, and MAGE-A3), a novel T cell inhibitory checkpoint receptor (TIGIT), and its respective ligands (PVR and PVRL2) as well as PDL1 from a cohort of NSCLC patients was analyzed. Immune cells from these patient samples were profiled and NYESO1/HLAA2 tetramer was used to detect NYESO1 specific CD8 T cells in HLAA2+ patients. Intracellular cytokine secretion was analyzed using a specially designed multiparameter flow cytometry panel for both general and NYESO-1+ CD8 T cells.


The correlation between CT antigens, immune checkpoints, and effector T cell signature (CD8A, IFN-gamma, and Granzyme A) may help us understand 1) why certain patients have inflamed tumors and others have “cold” tumors; 2) why certain patients respond to anti-PD(L)1 therapy and others do not respond. Antibodies targeting both PD1 and another novel immune checkpoint receptor TIGIT showed best stimulatory effect on both antigen specific CD8 T cell number and intracellular IFN-gamma staining of those cells.


The data suggest that immune checkpoint receptor antibodies can be screened in real patient immune cells. Cotargeting multiple immune checkpoint receptors may provide superior efficacy to targeting single immune checkpoint receptor.

Clinical trial identification

Not applicable

Legal entity responsible for the study

Eli Lilly and Company


Eli Lilly


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.